Results 81 to 90 of about 1,574,238 (214)
μ-Opioid Receptor Gene A118G Polymorphism Predicts Survival in Patients With Breast Cancer [PDF]
, 2012 Preclinical studies suggest that opioids may promote tumor growth. Genetic polymorphisms have been shown to affect opioid receptor function and to modify the clinical effects of morphine.
Arora, Harendra +5 more
core +1 more source
Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?
British Journal of Pharmacology, EarlyView.Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli +7 more
wiley +1 more source
NeurotherapeuticsNeuropathic pain poses a significant public health challenge, greatly impacting patients' quality of life. Emerging evidence underscores the involvement of epigenetics in dorsal root ganglion (DRG) neurons relevant to pain modulation.
Cheng-Yuan Lai +9 more
doaj +1 more source
Antidepressant-Like Effect of Venlafaxine Is Abolished in μ-Opioid Receptor–Knockout Mice
Journal of Pharmacological Sciences, 2010 Although the opioid system is known to modulate depression-like behaviors, its role in the effects of antidepressants is not yet clear. We investigated the role of μ-opioid receptors (MOPs) in the effects of venlafaxine, a serotonin and norepinephrine ...
Soichiro Ide +7 more
doaj +1 more source
The potential for biased signalling in the P2Y receptor family of GPCRs
British Journal of Pharmacology, EarlyView.The purinergic receptor family is primarily activated by nucleotides, and contains members of both the G protein coupled‐receptor (GPCR) superfamily (P1 and P2Y) and ligand‐gated ion channels (P2X). The P2Y receptors are widely expressed in the human body, and given the ubiquitous nature of nucleotides, purinergic signalling is involved with a plethora
Claudia M. Sisk +2 more
wiley +1 more source
Non-specific staining of μ-opioid receptors in DRG neurons.
, 2013 (A) Representative double immunofluorescence images showing similar μ-receptor and PGP 9.5 staining in DRG neurons of wild type mice (left panel) and μ/δ/κ-opioid receptor knockout mice (right panel).
Yvonne Schmidt (488909) +2 more
core +1 more source
Novel approaches for drug development against chronic primary pain: A systematic review
British Journal of Pharmacology, EarlyView.Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
Molecular Pain, 2015 Background In anesthetized rats and conscious humans, a gentle touch using a soft disc covered with microcones (with a texture similar to that of a finger), but not with a flat disc, inhibits nociceptive somatocardiac reflexes.
Nobuhiro Watanabe +2 more
doaj +1 more source
Specific staining of μ-opioid receptors in the sciatic nerve.
, 2013 Representative double immunofluorescence images showing μ-receptor and PGP 9.5 staining in the sciatic nerve of wild type mice (left panel), but only PGP 9.5 and no μ-receptor labeling in the μ/δ/κ-opioid receptor knockout mice (right panel). Omission of
Yvonne Schmidt (488909) +2 more
core +1 more source
Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders
British Journal of Pharmacology, EarlyView.Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman +3 more
wiley +1 more source